Mouse Models to Study Mechanisms of Drug Resistance in Immunotherapies & ADCs
Time: 11:30 am
day: Day Two
Details:
- Establishment and validation of in vivo and in vitro trastuzumab deruxtecan (Enhertu)-induced resistant tumor models
- Creation of syngeneic and engineered models of primary and acquired resistance to anti-PD1 therapies (e.g., CT26-PD1-R and B2M-KO models)
- Other humanized and syngeneic mouse models tailored for immune checkpoint inhibitors, ADCs, and combination of therapies
